Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2010

Seeber LM, Zweemer RP, Marchionni L, Massuger LF, Smit VT, W van Baal M, et al. Methylation profiles of endometrioid and serous endometrial cancers. Endocr Relat Cancer. 2010;17(3):663-73.

Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 2010;16(3):286-94.

Seidman JD, Cosin JA, Wang BG, Alsop S, Yemelyanova A, Fields A, et al. Upstaging pathologic stage I ovarian carcinoma based on dense adhesions is not warranted: a clinicopathologic study of 84 patients originally classified as FIGO stage II. Gynecol Oncol. 2010;119(2):250-4.

Loda M, Kaelin WG. Prostate cancer: beta control your hormones. Cancer Cell. 2010;17(4):311-2.

Triantafyllopoulou A, Franzke C-, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, et al. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci U S A. 2010;107(7):3012-7.

Hood M, Yu K, Magro C, Reisacher W. Pathology quiz case 2. Subcutaneous Sweet syndrome of the neck. Arch Otolaryngol Head Neck Surg. 2010;136(10):1038, 1040-1.

Panarelli NC, Furman RR, Y Wang L, Elstrom R, Cohen JA, Chadburn A. NK/T cell non-Hodgkin lymphoma in a HIV-positive patient. J Hematop. 2010;3(1):35-40.

Greenblatt MB, Aliprantis A, Hu B, Glimcher LH. Calcineurin regulates innate antifungal immunity in neutrophils. J Exp Med. 2010;207(5):923-31.

Cushing M, Degtyaryova D, Lomas-Francis C. Transfusion medicine illustrated. The role of plasmapheresis in the multimodal treatment of anti-Pr cold agglutinin disease. Transfusion. 2010;50(10):2100-1.

Scandurra M, Mian M, Greiner TC, Rancoita PM, De Campos CP, Chan WC, et al. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Br J Haematol. 2010;151(3):221-31.